Jiangxi Tonghe Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") recently learned from the National Medical Products Administration's Center for Drug Evaluation (CDE) "Raw and Auxiliary Material Registration Information Publicity" platform that the raw material drug "Celecoxib" submitted by the Company has passed CDE approval. The specific details are as follows:
300636SZSE
🚨 Material Event
Announcement on the Approval of the Company's Raw Material Drug by CDE
✨ AI Summary
Jiangxi Tonghe Pharmaceutical Co., Ltd. announced that its raw material drug "Celecoxib" has been approved by the CDE. This approval indicates compliance with Chinese drug review standards and allows for domestic market sales. The company aims to expand its product sales both domestically and internationally, although specific sales outcomes may vary due to market conditions.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.